Sarepta Therapeutics' (SRPT) Outperform Rating Reaffirmed at William Blair

Key Points

• Sarepta Therapeutics' stock has received an "outperform" rating from William Blair, in contrast to mixed ratings from other analysts including a downgrade to "hold" from Baird R W.
• The company's stock price recently increased to $16.93, though it has experienced significant volatility, with a 1-year low of $10.41 and a high of $146.38.
• Despite reporting a quarterly revenue of $744.86 million, Sarepta posted a substantial earnings miss with an EPS of ($3.42), falling short of analyst expectations.

William Blair reaffirmed their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a report published on Tuesday morning,RTT News reports.

Several other brokerages have also recently issued reports on SRPT. Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Jefferies Financial Group reduced their price target on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Thursday, July 24th. Wells Fargo & Company reduced their price target on shares of Sarepta Therapeutics from $65.00 to $48.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Royal Bank Of Canada reduced their price target on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating on the stock in a research report on Thursday, July 17th. Finally, Barclays downgraded shares of Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday. Six research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and a consensus target price of $49.12.

Sarepta Therapeutics Stock Down 2.8%

Shares of SRPT traded down $0.45 during mid-day trading on Tuesday, hitting $15.97. 2,801,752 shares of the company's stock were exchanged, compared to its average volume of 5,726,139. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -5.95 and a beta of 0.45. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $145.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The stock's 50-day moving average is $24.24 and its 200-day moving average is $61.50.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 EPS. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SRPT. Capital International Investors lifted its position in Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $126,315,000. Aberdeen Group plc increased its stake in Sarepta Therapeutics by 91.1% in the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company's stock valued at $21,500,000 after buying an additional 592,125 shares during the period. Assenagon Asset Management S.A. increased its stake in Sarepta Therapeutics by 438.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after buying an additional 580,123 shares during the period. Finally, Wellington Management Group LLP increased its stake in Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after buying an additional 577,848 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.